324 related articles for article (PubMed ID: 26676609)
1. Therapeutic targeting of casein kinase 1δ in breast cancer.
Rosenberg LH; Lafitte M; Quereda V; Grant W; Chen W; Bibian M; Noguchi Y; Fallahi M; Yang C; Chang JC; Roush WR; Cleveland JL; Duckett DR
Sci Transl Med; 2015 Dec; 7(318):318ra202. PubMed ID: 26676609
[TBL] [Abstract][Full Text] [Related]
2. IC261 induces cell cycle arrest and apoptosis of human cancer cells via CK1δ/ɛ and Wnt/β-catenin independent inhibition of mitotic spindle formation.
Cheong JK; Nguyen TH; Wang H; Tan P; Voorhoeve PM; Lee SH; Virshup DM
Oncogene; 2011 Jun; 30(22):2558-69. PubMed ID: 21258417
[TBL] [Abstract][Full Text] [Related]
3. Development of dual casein kinase 1δ/1ε (CK1δ/ε) inhibitors for treatment of breast cancer.
Monastyrskyi A; Nilchan N; Quereda V; Noguchi Y; Ruiz C; Grant W; Cameron M; Duckett D; Roush W
Bioorg Med Chem; 2018 Feb; 26(3):590-602. PubMed ID: 29289448
[TBL] [Abstract][Full Text] [Related]
4. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
Ma L; Wang X; Jia T; Wei W; Chua MS; So S
Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of β-catenin signaling suppresses pancreatic tumor growth by disrupting nuclear β-catenin/TCF-1 complex: critical role of STAT-3.
Pramanik KC; Fofaria NM; Gupta P; Ranjan A; Kim SH; Srivastava SK
Oncotarget; 2015 May; 6(13):11561-74. PubMed ID: 25869100
[TBL] [Abstract][Full Text] [Related]
6. Baicalein suppresses metastasis of breast cancer cells by inhibiting EMT via downregulation of SATB1 and Wnt/β-catenin pathway.
Ma X; Yan W; Dai Z; Gao X; Ma Y; Xu Q; Jiang J; Zhang S
Drug Des Devel Ther; 2016; 10():1419-41. PubMed ID: 27143851
[TBL] [Abstract][Full Text] [Related]
7. ERN1 and ALPK1 inhibit differentiation of bi-potential tumor-initiating cells in human breast cancer.
Strietz J; Stepputtis SS; Preca BT; Vannier C; Kim MM; Castro DJ; Au Q; Boerries M; Busch H; Aza-Blanc P; Heynen-Genel S; Bronsert P; Kuster B; Stickeler E; Brabletz T; Oshima RG; Maurer J
Oncotarget; 2016 Dec; 7(50):83278-83293. PubMed ID: 27829216
[TBL] [Abstract][Full Text] [Related]
8. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
9. The role of PIP5K1α/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1α inhibitor.
Sarwar M; Syed Khaja AS; Aleskandarany M; Karlsson R; Althobiti M; Ødum N; Mongan NP; Dizeyi N; Johnson H; Green AR; Ellis IO; Rakha EA; Persson JL
Oncogene; 2019 Jan; 38(3):375-389. PubMed ID: 30104711
[TBL] [Abstract][Full Text] [Related]
10. Computational design, chemical synthesis, and biological evaluation of a novel ERK inhibitor (BL-EI001) with apoptosis-inducing mechanisms in breast cancer.
Liu B; Fu L; Zhang C; Zhang L; Zhang Y; Ouyang L; He G; Huang J
Oncotarget; 2015 Mar; 6(9):6762-75. PubMed ID: 25742792
[TBL] [Abstract][Full Text] [Related]
11. Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase.
Vena F; Bayle S; Nieto A; Quereda V; Aceti M; Frydman SM; Sansil SS; Grant W; Monastyrskyi A; McDonald P; Roush WR; Teng M; Duckett D
Mol Cancer Ther; 2020 Aug; 19(8):1623-1635. PubMed ID: 32430484
[TBL] [Abstract][Full Text] [Related]
12. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
Arqués O; Chicote I; Puig I; Tenbaum SP; Argilés G; Dienstmann R; Fernández N; Caratù G; Matito J; Silberschmidt D; Rodon J; Landolfi S; Prat A; Espín E; Charco R; Nuciforo P; Vivancos A; Shao W; Tabernero J; Palmer HG
Clin Cancer Res; 2016 Feb; 22(3):644-56. PubMed ID: 26224873
[TBL] [Abstract][Full Text] [Related]
13. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.
Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
Oncotarget; 2015 Feb; 6(5):2623-40. PubMed ID: 25739118
[TBL] [Abstract][Full Text] [Related]
14. Cardamonin, a chalcone, inhibits human triple negative breast cancer cell invasiveness by downregulation of Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition.
Shrivastava S; Jeengar MK; Thummuri D; Koval A; Katanaev VL; Marepally S; Naidu VGM
Biofactors; 2017 Mar; 43(2):152-169. PubMed ID: 27580587
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
16. Effects of altered expression and activity levels of CK1δ and ɛ on tumor growth and survival of colorectal cancer patients.
Richter J; Ullah K; Xu P; Alscher V; Blatz A; Peifer C; Halekotte J; Leban J; Vitt D; Holzmann K; Bakulev V; Pinna LA; Henne-Bruns D; Hillenbrand A; Kornmann M; Leithäuser F; Bischof J; Knippschild U
Int J Cancer; 2015 Jun; 136(12):2799-810. PubMed ID: 25404202
[TBL] [Abstract][Full Text] [Related]
17. Prodigiosin inhibits Wnt/β-catenin signaling and exerts anticancer activity in breast cancer cells.
Wang Z; Li B; Zhou L; Yu S; Su Z; Song J; Sun Q; Sha O; Wang X; Jiang W; Willert K; Wei L; Carson DA; Lu D
Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13150-13155. PubMed ID: 27799526
[TBL] [Abstract][Full Text] [Related]
18. CK1δ as a potential therapeutic target to treat bladder cancer.
Lin YC; Chen MC; Hsieh TH; Liou JP; Chen CH
Aging (Albany NY); 2020 Apr; 12(7):5764-5780. PubMed ID: 32282334
[TBL] [Abstract][Full Text] [Related]
19. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
[TBL] [Abstract][Full Text] [Related]
20. CK1delta modulates the transcriptional activity of ERalpha via AIB1 in an estrogen-dependent manner and regulates ERalpha-AIB1 interactions.
Giamas G; Castellano L; Feng Q; Knippschild U; Jacob J; Thomas RS; Coombes RC; Smith CL; Jiao LR; Stebbing J
Nucleic Acids Res; 2009 May; 37(9):3110-23. PubMed ID: 19339517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
